Education
About Us
Working with TipRanks
Follow Us
PYC Therapeutics Limited (AU:PYC)
ASX:PYC
Total Valuation
PYC Therapeutics Limited has a market cap or net worth of AU$711.58M. The enterprise value is AU$549.20M.
Market CapAU$711.58M
Enterprise ValueAU$549.20M
Share Statistics
PYC Therapeutics Limited has 583,260,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding583,260,440
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
PYC Therapeutics Limited’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -16.84%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-16.84%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee1.02M
Profits Per Employee0.00
Employee Count23
Asset Turnover0.13
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PYC Therapeutics Limited is ―. PYC Therapeutics Limited’s PEG ratio is -0.01.
PE Ratio―
PS Ratio27.69
PB Ratio3.84
Price to Fair Value3.84
Price to FCF-12.39
Price to Operating Cash Flow-85.82
PEG Ratio-0.01
Income Statement
In the last 12 months, PYC Therapeutics Limited had revenue of 23.49M and earned -50.30M in profits. Earnings per share was -0.10.
Revenue23.49M
Gross Profit23.49M
Operating Income-53.63M
Pretax Income-51.01M
Net Income-50.30M
EBITDA-52.88M
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was -51.56M and capital expenditures -975.40K, giving a free cash flow of -52.54M billion.
Operating Cash Flow-51.56M
Free Cash Flow-52.54M
Free Cash Flow per Share-0.09
Dividends & Yields
PYC Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change-34.64%
50-Day Moving Average1.19
200-Day Moving Average1.22
Relative Strength Index (RSI)53.94
Average Volume (3m)1.00M
Important Dates
PYC Therapeutics Limited upcoming earnings date is Feb 26, 2026, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
PYC Therapeutics Limited as a current ratio of 14.41, with Debt / Equity ratio of 2.18%
Current Ratio14.41
Quick Ratio14.41
Debt to Market Cap<0.01
Net Debt to EBITDA2.88
Interest Coverage Ratio-861.87
Taxes
In the past 12 months, PYC Therapeutics Limited has paid -23.49M in taxes.
Income Tax-23.49M
Effective Tax Rate0.46
Enterprise Valuation
PYC Therapeutics Limited EV to EBITDA ratio is -9.43, with an EV/FCF ratio of -9.49.
EV to Sales21.22
EV to EBITDA-9.43
EV to Free Cash Flow-9.49
EV to Operating Cash Flow-9.67
Balance Sheet
PYC Therapeutics Limited has AU$153.05M in cash and marketable securities with AU$1.02M in debt, giving a net cash position of AU$152.03M billion.
Cash & Marketable SecuritiesAU$153.05M
Total DebtAU$1.02M
Net CashAU$152.03M
Net Cash Per ShareAU$0.26
Tangible Book Value Per ShareAU$0.33
Margins
Gross margin is 100.00%, with operating margin of -228.26%, and net profit margin of -214.11%.
Gross Margin100.00%
Operating Margin-228.26%
Pretax Margin-217.13%
Net Profit Margin-214.11%
EBITDA Margin-225.06%
EBIT Margin-228.26%
Analyst Forecast
The average price target for PYC Therapeutics Limited is AU$2.58, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$2.58
Price Target Upside120.51% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-5.70%